2 views left Get unlimited views with a free account

Subscribe to GlobalData Explorer

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Duchenne Muscular Dystrophy by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 337 ongoing clinical trials involving Duchenne Muscular Dystrophy
Of the 337 trials,184 trials are in Phase III
Furthermore, 54 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Duchenne Muscular Dystrophy by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Duchenne Muscular Dystrophy, Genetic disorders.The largest number of ongoing clinical trials of Duchenne Muscular Dystrophy is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions involved in Duchenne Muscular Dystrophy-related drug trials.

Sarepta Therapeutics Inc:The leading ongoing Colitis-related clinical trial sponsor

Sarepta Therapeutics Inc, the US-based pharmaceuticals company, is the top sponsor for Duchenne Muscular Dystrophy-related ongoing clinical trials.

PTC Therapeutics Inc, NS Pharma Inc, Nationwide Children's Hospital, FibroGen Inc, and ItalfarmacoSpAare a few other notable sponsors involved inDuchenne Muscular Dystrophy.A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Duchenne Muscular Dystrophy

Eteplirsen (Exondys 51), Ataluren (Translarna), Deflazacort (MP-104, Emflaza), and Viltepso are among the key marketed drugs involving Duchenne Muscular Dystrophy.

Eteplirsen (Exondys 51) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer.It functions via the Dystrophin (DMD) Activator mechanism of action. It is formulated as a powder for suspension for the subcutaneous route of administration. It is formulated as an injectable powder for a solution and concentrate for solution for intravenous route of administration. Exondys 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. Eteplirsen was first approved in 2016 and is marketed in the US, and Israel by Sarepta Therapeutics Inc.

Ataluren (Translarna) is a benzoic acid derivative that acts against muscular dystrophy.It functions via the Cystic Fibrosis Transmembrane Conductance Regulator (ATP Binding Cassette Sub Family C Member 7 or Channel Conductance Controlling ATPase Camp Dependent Chloride Channel or ABCC7 or CFTR or EC 5.6.1.6) Blocker mechanism of action. It is formulated as granules and powder for suspension for the oral route of administration. Translarna is indicated for the treatment of Duchenne Muscular Dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 5 years and older and also in non-ambulatory patients. Ataluren was first approved in 2014 and is marketed in the UK, Germany, and France by PTC Therapeutics Inc.